Oramed Pharmaceuticals ORMP Income Statement (2010-2026)

NASDAQ ORMP
$4.79 +0.00 (+0.00%)
At close: Aug 20, 2026 · 4:00 PM EDT
1Y3Y5Y7Y10YAll
Download Data
Income Statement Nov2010 Feb2011 May2011 Aug2011 Nov2011 Feb2012 May2012 Aug2012 Nov2012 Feb2013 May2013 Aug2013 Nov2013 Feb2014 May2014 Aug2014 Nov2014 Feb2015 May2015 Aug2015 Nov2015 Feb2016 May2016 Aug2016 Nov2016 Feb2017 May2017 Aug2017 Nov2017 Feb2018 May2018 Aug2018 Nov2018 Feb2019 May2019 Aug2019 Nov2019 Feb2020 May2020 Aug2020 Nov2020 Feb2021 May2021 Aug2021 Nov2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
28.47M38.09M38.68M38.80M39.10M39.00M40.04M40.23M40.28M40.34M40.52M40.63M40.21M39.92M40.85M40.85M40.84M39.28M40.93M41.60M
Revenue & cost
Revenue (Quarter)
2.70M0.67M0.67M0.68M0.90M0.67M0.67M2.00M
Gross Profit (Quarter)
0.01M
Operating items
Research & Development (Quarter)
20.99M5.84M0.38M0.46M9.04M4.43M1.82M0.96M1.77M1.18M1.44M2.24M1.46M2.21M1.03M1.15M1.99M1.59M
Selling, General & Administrative (Quarter)
5.49M2.53M3.06M2.73M1.26M2.45M2.60M2.11M1.78M1.69M0.85M2.13M2.31M1.46M1.27M3.68M2.06M2.77M
Operating Expenses (Quarter)
20.99M11.33M2.91M3.52M11.76M5.69M4.27M3.56M3.88M2.96M3.13M3.09M3.60M4.51M2.49M2.43M5.67M3.66M2.77M
Operating Income (Quarter)
-24.22M-11.25M-11.42M-8.19M-12.33M-5.21M-3.79M-2.89M-3.88M-2.96M-3.13M-3.09M-3.60M-4.50M-2.49M-2.43M-5.67M-3.66M-2.77M
EBIT (Quarter)
-24.22M-11.25M-11.42M-8.19M-12.33M-5.21M-3.79M-2.89M-3.88M-2.96M-3.13M-3.09M-3.60M-4.50M-2.49M-2.43M-5.67M-3.66M-2.77M
Non-operating items
Non Operating Investment Income (Quarter)
Interest & Investment Income (Quarter)
1.24M0.54M0.35M0.16M1.60M2.48M0.65M0.28M
Other Non Operating Income (Quarter)
3.55M16.65M-20.09M0.26M8.90M32.28M-39.17M-0.05M-0.00M
Non Operating Income (Quarter)
1.04M1.00M1.60M2.48M0.43M18.38M5.09M14.23M-15.42M-6.19M-2.56M15.37M61.47M15.18M44.85M103.74M
Net income details
EBT (Quarter)
-22.99M-11.65M-12.10M-7.15M-12.26M-3.62M-1.31M-3.28M13.30M1.53M10.84M-18.51M-9.78M-7.06M13.13M59.45M9.80M49.44M101.59M
Tax Provisions (Quarter)
0.10M-0.20M1.63M1.13M0.42M0.58M-0.13M11.06M-11.40M11.13M23.43M
Profit After Tax (Quarter)
-22.99M-10.71M-10.53M-7.06M-12.26M-3.40M-1.19M-3.22M12.90M1.54M9.21M-19.62M-10.20M-7.64M13.26M48.40M29.31M38.31M78.16M
Income from Non-Controlling Interests (Quarter)
-0.75M-0.28M-0.53M-0.19M-0.59M-0.22M-0.12M-0.06M0.83M-0.00M-0.01M-0.02M-0.01M-0.03M-0.01M
Income from Continuing Operations (Quarter)
-22.99M-11.65M-12.10M-7.25M-12.05M-3.62M-1.31M-3.28M13.30M1.53M9.20M-19.64M-10.20M-7.64M13.26M48.39M21.20M38.31M78.16M
Consolidated Net Income (Quarter)
-22.99M-11.65M-12.10M-7.25M-12.05M-3.62M-1.31M-3.28M13.30M1.53M9.20M-19.64M-10.20M-7.64M13.26M48.39M21.20M38.31M78.16M
Income towards Parent Company (Quarter)
-22.99M-11.65M-12.10M-7.25M-12.05M-3.62M-1.31M-3.28M13.30M1.53M9.20M-19.64M-10.20M-7.64M13.26M48.39M21.20M38.31M78.16M
Net Income towards Common Stockholders (Quarter)
-22.24M-10.43M-10.53M-7.06M-11.67M-3.40M-1.31M-3.28M13.30M1.53M9.20M-19.64M-10.20M-7.64M13.26M48.39M21.20M38.31M78.16M
Additional items
EPS (Basic) (Quarter)
-0.78-0.27-0.27-0.18-0.30-0.08-0.03-0.080.330.040.22-0.48-0.25-0.190.321.160.510.941.84
EPS (Diluted) (Quarter)
-0.78-0.27-0.27-0.18-0.30-0.08-0.03-0.080.330.040.22-0.48-0.25-0.190.311.130.500.911.84
Shares Outstanding (Quarter)
28.47M36.67M38.68M38.80M39.10M39.00M40.04M40.23M40.45M40.32M40.84M40.96M40.90M40.83M41.23M41.74M41.76M41.40M40.77M42.50M
Shares Outstanding (Diluted) (Quarter)
28.47M34.54M38.68M38.80M39.10M39.00M40.04M40.23M40.45M40.57M41.56M41.59M40.90M40.83M41.23M42.61M42.77M42.42M41.97M42.50M
EBITDA (Quarter)
-24.22M-11.25M-11.42M-8.19M-12.33M-5.21M-3.79M-2.89M-3.88M-2.96M-3.13M-3.09M-3.60M-4.50M-2.49M-2.43M-5.67M-3.66M-2.77M
Interest Expenses (Quarter)
0.01M0.53M0.94M1.04M0.95M0.09M0.01M0.76M0.83M2.95M0.59M0.26M0.45M-2.05M0.01M0.13M0.13M0.12M0.16M0.84M
Tax Rate (Quarter)
-1.401.6315.08-6.12-4.25-8.27-0.9618.61-116.3422.5123.06